Mile High Compounds has a large, multi-laboratory testing archive with detailed purity, content and contamination results. Its public collection contains 197 observations: 174 complete report sets, including 94 matched to official issuer records, plus 23 historical observations whose files are unavailable. A specific historical IGF-1 LR3 report records a sterility failure, and an FDA warning letter dated March 31, 2026 addresses the company's marketing and intended-use claims.
This guide explains how to use that archive, which findings need attention, what customer-review sources show and how the published return terms work. It preserves the evidence reviewed on October 16, 2026. PeptidePrices no longer lists or partners with Mile High Compounds and has no affiliate link or coupon for it.
What Mile High Compounds sells
Mile High Compounds sells research peptides and related products through milehighcompounds.is. On October 15, 2026 its catalog had 82 offers, 81 of them in stock: 56 lyophilized vials, 10 capsule products, 8 oral or injectable liquids and 8 mist applicators. A few examples of the prices seen that day: BPC-157 10 mg at $49.99, TB-500 10 mg at $59.99 and MOTS-c 10 mg at $49.99. Prices change, so treat these as a dated snapshot and not a quote.
The site says every product is for laboratory research use only, is not FDA-approved, and that the company is not a 503A compounding pharmacy.
Who runs it
The FDA letter names Mile High Compounds LLC and is addressed to Max Radovanic in Clifton, Colorado. The company's own site describes a family business in Colorado Springs, Colorado, ships orders from Scottsdale, Arizona, and names its founder only as Max. These sources describe different locations for the FDA correspondence, the business and dispatch. The site publishes a contact form and support email, but no street address or phone number.
The domain was registered on July 9, 2025, according to the ISNIC register. The company says its products come from cGMP-certified quality systems and audited facilities, but it does not name the manufacturers, and PeptidePrices could not verify the claim.
The FDA warning letter
The FDA warning letter is dated March 31, 2026. The FDA's Center for Drug Evaluation and Research, through its Office of Unapproved Drugs and Labeling Compliance, issued it. Here is what the letter says:
- Products named. The letter lists GLP-1 SM, GLP-2 TRZ, GLP-3 RT and BAC Water as unapproved new drugs. It treats the bacteriostatic water as a drug because it is sold with injectable peptide products.
- Basis. The FDA relied on content on the company's website, material from community forums and product labeling. It concluded that this content showed the products were intended for human use. It does not accept the research-only labels as a defense.
- No laboratory findings. The letter reports no testing of the products. It is a statement about how the products were marketed, not a finding about what was in the vials.
- Status. The letter asks for a written response within 15 working days. The FDA page lists no close-out letter, and PeptidePrices found no public resolution. PeptidePrices does not know whether the company responded.
Read the letter for its stated marketing findings and the named products; use the individual laboratory reports below for analytical results.
The testing archive
The company's COA library supplies the source documents. The public PeptidePrices collection includes 174 complete sets and 23 historical observations with unavailable files, for 197 observations in total. Of the complete public sets, 94 matched official issuer records.
The broader October 16 review covered 191 complete report sets across 74 products, including 17 complete reports outside the public compound scope. That broader review found 102 issuer matches. The following laboratory totals describe those 191 sets; they are not the public collection's counts:
| Laboratory | Report sets |
|---|---|
| Vanguard Laboratory | 63 |
| Kovera Labs | 52 |
| Chromate | 46 |
| Ethos Analytics | 13 |
| ILS Laboratories | 12 |
| Freedom Diagnostics | 3 |
| Janoshik | 2 |
Depth. Endotoxin and heavy-metal results appear on 145 of the 191 sets (76%), sterility on 112, and fentanyl screens on selected sets. The fullest reports run to 11 or 12 tests, including residual solvents, TFA, solubility and seal integrity. Many products have per-vial reports. The Adamax 10 mg report, for example, shows four vial measurements with a minimum purity of 99.876% and a minimum content of 11.21 mg, with LC-MS identity. The company says each new lot runs a 15-point panel and that up to 18 vials are sampled. PeptidePrices did not find that depth on every report, so it treats the statement as the company's own claim.
Verification. 102 of the 191 sets match a record in the issuing laboratory's own system: Kovera 46, Chromate 26, Vanguard 25, Freedom Diagnostics 3 and Janoshik 2. The other 89 complete files had no matched issuer record (Vanguard 38, Chromate 20, Ethos 13, ILS 12 and Kovera 6). Vanguard's public index is opt-in and does not include every issued report. In the narrower public collection, 94 of 174 complete sets are issuer-matched; the 23 unavailable historical observations remain separate from complete files and verified results.
Product matching. On October 15, 2026, 46 catalog offers carried an exact reviewed certificate for compound, per-vial strength and formulation. The rest do not: some reports could not be matched to the issuer, some show a label strength that differs from the report (for example 25 mg commercial products against 20 mg reports), and some current lots have no report in the archive. Check the lot number on your vial against the lot on the certificate.
Failures and weak results
PeptidePrices found one printed failure. Vanguard report V260210-9 001 for IGF-1 LR3, dated February 27, 2026, prints "Fail - Growth Detected" for its USP 71 sterility test. That batch was lot IGF-001-MH-02. The product certificate reviewed October 15, 2026 covers a later lot (MH-03, Kovera Labs, May 19, 2026). Keep the failed historical lot and the later product certificate separate when checking a vial.
Other reports record low purity or measured-content exceptions that matter when reading the archive:
- IGF-1 LR3 at 90.019% purity (Chromate report 28807, October 22, 2025).
- NAD+ 500 mg at 91.304% purity (Chromate report 28798, October 8, 2025) and 93.706% (Chromate report 30337, December 13, 2025).
- Methylene Blue 20 mg report 28566, which measured 13.69, 14.87 and 13.53 mg across three samples, below the label, with Azure B at 10.344%, 10.495% and 10.271% against a printed limit of 10%.
What customers say
Trustpilot. PeptidePrices saw the exact-domain Trustpilot profile at 4.7 out of 5 from 442 reviews on August 14, 2026. The profile had been removed by October 15, 2026, so treat that figure as historical. The retained August observation is a historical customer-review signal, not a current aggregate rating.
The company's own review page. The review page on the company site shows 483 reviews averaging 4.9. Of those, 482 are archived from earlier platforms, and the page is hosted by the company, so the count describes a merchant-hosted collection.
Peptide Critic user posts. PeptidePrices read the individual customer reviews that members posted on Peptide Critic, and not the site's own ratings. Most were five-star. They describe a professional vendor, good selection and quick communication. One four-star review says prices are high even with codes, that shipping to the East Coast was slow and that shipping protection was required, and it says the buyer would order again. Several of the posts were submitted under the site's account and not by a named member. These are user posts, not verified purchases.
Disclosed Labs. The review site Disclosed Labs graded the company B (84 out of 100) on October 6, 2026, based on 63 attributed lab reports, 61 passing and 2 failing. Both failures were the NAD+ purity results listed above. Disclosed Labs says its scores are its own opinion from the available data and are not blind-purchase testing, so this is an outside reading of the same published reports and not a customer review.
Shipping, payment and returns
The company's FAQ says U.S. orders over $250 ship free by FedEx 2 Day, while the homepage says $300, so the two pages disagree. Orders placed by 3 p.m. Mountain time on weekdays, or noon on Saturday, are scheduled to ship the same day from Scottsdale. International orders ship delivered-duty-paid through GlobalPost. The FAQ lists major credit cards, Apple Pay and bank transfer. PeptidePrices did not complete a checkout, so it did not verify that any of these methods works.
The refund policy accepts unused, unopened, factory-sealed product if the return starts within 14 days of purchase. Refunds are store credit only, and original shipping is not refunded. Damaged or missing items must be reported within seven days of delivery, and separate protection terms give a different window of 14 days. Submitted orders cannot be changed. Community reviewers report required shipping protection and slow delivery to the East Coast.
How to use the evidence
Start with the exact compound, strength, formulation and lot on the vial. A report from another lot or a different nominal amount cannot establish the contents of that unit. The 46 offers with exact reviewed certificates are an October 15, 2026 catalog snapshot; use a current product's certificate to check the lot now offered.
Open the issuing laboratory's record where one exists and compare the complete document. Keep purity, measured content, endotoxin, metals and sterility as separate results. The historical IGF-1 LR3 sterility failure and the Methylene Blue measurements above are report-specific findings, not a description of every product in the archive.
For customer service, distinguish the removed Trustpilot profile's historical average from the company's hosted review collection and individual community posts. Before ordering, resolve the conflicting free-shipping thresholds and read the store-credit-only return policy.
The COA verification guide explains how to compare issuer records, and the vendor vetting checklist covers operating identity and policies.
Sources
- FDA warning letter to Mile High Compounds LLC, March 31, 2026 (MARCS-CMS 721600)
- Mile High Compounds COA library
- Mile High Compounds FAQ
- Mile High Compounds refund policy
- Mile High Compounds review page
- Trustpilot: Mile High Compounds (historical profile)
- Peptide Critic member posts about Mile High Compounds, read October 2026
- Disclosed Labs vendor grade, October 6, 2026
General information only. Not medical advice. PeptidePrices does not sell peptides, does not list Mile High Compounds, and has no affiliate relationship with it.